Q-omics provides the consensus-scored ZNF878 profile across patient tissues and cancer cell-line models. ZNF878 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF878 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ZNF878 RNA expression shows 18,927 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where ZNF878 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF878 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF878 survival associations across molecular data types. ZNF878 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF878 RNA expression–survival associations across cancer types. High ZNF878 expression shows unfavorable associations in LIHC, LGG, KICH, UVM and LUSC, but favorable associations in READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF878 RNA expression.
This table summarizes ZNF878 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF878. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF878 shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD, STAD, UCEC and READ. The KIRC box plot shows higher ZNF878 RNA expression in normal versus tumor tissue (log2 FC = −0.508, t-test p < 0.001).
This table shows molecular features associated with ZNF878 in patient tissues and cancer cell lines. In patient samples, ZNF878 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF878 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
